Language selection

Search

Details for: TYSABRI

Company: BIOGEN CANADA INC

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02286386TYSABRINATALIZUMAB300 MG / 15 MLSOLUTIONINTRAVENOUS
Search Reported Side Effects Report a Side Effect

Summary Reports

Summary Basis of Decision
Summary Safety Review - TYSABRI (natalizumab) - Blood (hematological) Abnormalities in Newborns whose Mothers were treated with Tysabri During Pregnancy
Summary Safety Review - TYSABRI (natalizumab) - Assessing the Potential Risk of Hemolytic Anemia

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: